Dr. Borghaei on Second-Line Therapy in SCLC
November 10th 2018Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the evolving second line of treatment in small cell lung cancer.
Read More
Dr. Borghaei Discusses the PACIFIC Trial in Lung Cancer
February 27th 2018Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the PACIFIC trial in patients with non–small cell lung cancer (NSCLC).
Read More
Dr. Borghaei on Reporting Immunotherapy-Related AEs in Lung Cancer
January 20th 2017Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.
Read More
Dr. Borghaei on the Management of Immune-Related Side Effects in Lung Cancer
November 16th 2016Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the management of slightly rarer side effects that patients with lung cancer can experience when treated with immunotherapy agents.
Read More
Dr. Borghaei on 2-Year Findings With Nivolumab Vs Docetaxel in NSCLC
June 4th 2016Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non–small cell lung cancer (NSCLC).
Read More